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Background  :  Although  benzalkonium  chloride  (BAC)-induced  bronchoconstriction  occurs  in  patients  with  bronchial 
asthma,  BAC-containing  nebulizer  solutions  are  still  being  used  in  daily  practice  in  Korea.  The  aim  of  this  study  was 
to  evaluate  the  effects  of  inhaled  aqueous  solutions  containing  BAC. 
Methods  :  Thirty  subjects  with  bronchial  asthma  and  10  normal  controls  inhaled  up  to  three  600  μg  nebulized 
doses  of  BAC  using  a  jet  nebulizer.  FEV1  (forced  expiratory  volume  at  one  second)  was  measured  15  minutes  after 
each  dose.  Inhalations  were  repeated  every  20  minutes  until  FEV1  decreased  by  15%  or  more  (defined  as 
BAC-induced  bronchoconstriction)  or  the  3  doses  were  administered. 
Results  :  The  percent  fall  in  FEV1  in  response  to  BAC  inhalation  was  significantly  higher  in  asthmatics  than  in 
normal  subjects  (p<0.05).  BAC  administration  in  subjects  with  asthma  reached  a  plateau  (maximal  effect).  BAC-induced 
bronchoconstriction  was  found  in  6  asthmatics  (20%),  with  two  responders  after  the  2
nd  inhalation  and  4  after  the  3
rd 
inhalation.  The  percent  fall  in  FEV1  in  response  to  the  1
st  inhalation  of  BAC  was  significantly  higher  in  asthmatics  with 
higher  bronchial  hyperresponsiveness  (BHR)  than  in  those  with  lower  BHR.
Conclusions  :  This  study  suggests  that  the  available  multi-dose  nebulized  solution  is  generally  safe.  However, 
significant  bronchoconstriction  can  occur  at  a  relatively  low  BAC  dose  in  asthmatics  with  severe  airway  responsiveness.
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INTRODUCTION
Benzalkonium  chloride  (BAC)  is  one  of  several  quaternary 
ammonium  compounds  used  in  pharmaceuticals  as  antiseptics 
and  disinfectants
1).  It  is  also  the  most  common  preservative  in 
nebulizer  solutions.  BAC  has  been  associated  with  unintended 
bronchoconstriction  after  use  of  aerosolized  asthma  medications 
and  after  occupational  exposure
1, 2).  For  example,  isotonic 
ipratropium  bromide  inhalation  solution  containing  0.25  mg/mL 
BAC  caused  significant  bronchoconstriction  in  patients  with 
asthma  (20%  drop  of  FEV1  in  6  of  22  subjects)
3),  and 
BAC-induced  bronchoconstriction  has  been  documented  in 
successive  studies
4-6).  BAC  in  nebulizer  solutions  may  also  lead 
to  respiratory  arrest
7).
These  reports  provoked  a  worldwide  call  for  the  withdrawal  of 
BAC  from  nebulizer  solutions
8).  Although  most  BAC-containing 
nebulizer  solutions  disappeared  from  clinical  use,  0.5%  albuterol 
(salbutamol)  non-sterile  solution,  which  contains  50  μg  of  BAC 
per  2.5  mg  of  albuterol,  is  still  frequently  prescribed  in  everyday 
practice  for  the  treatment  of  bronchial  asthma  in  Korea. 
We  therefore  evaluated  the  effect  of  BAC  inhalation  in 
patients  with  stable  bronchial  asthma  to  assess  the  safety  of 
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MATERIALS AND METHODS
Subjects
Among  patients  with  stable  bronchial  asthma  who  had  visited 
our  outpatient  clinic,  30  patients  with  a  baseline  FEV1  of  65%  or 
greater  of  the  predicted  value  were  selected  for  this  study. 
Bronchial  asthma  was  diagnosed  by  the  presence  of  symptoms 
compatible  of  bronchial  asthma  and  positive  results  in  a 
methacholine  bronchial  provocation  test  (MBPT)  or  bronchodi-
lator  response  (BDR).  MBPT  was  considered  positive  when  the 
methacholine  concentration  needed  to  decrease  post-provocation 
FEV1  by  more  than  20%  of  the  baseline  value  (methacholine 
PC20  FEV1)  was  less  than  25  mg/mL,  and  BDR  was  deemed 
positive  when  the  post-bronchodilator  increase  of  FEV1  was 
more  than  12%  of  the  pre-bronchodilator  value.  Stable  bronchial 
asthma  was  defined  as  asthma  with  no  asthmatic  attack 
resulting  in  a  hospital  visit  during  two  recent,  consecutive 
months;  no  change  of  medication  due  to  exacerbation;  and 
FEV1  changes  of  less  than  10%  of  the  patient's  best  FEV1. 
Subjects  with  a  history  of  life-threatening  asthma  or 
anaphylaxis  were  excluded  from  the  study.  Other  reasons  for 
exclusion  were  an  emergency  department  visit,  hospitalization 
for  asthma  within  the  previous  3  months,  a  reported  use  of  oral 
corticosteroids  within  the  previous  3  months,  or  a  respiratory 
tract  infection  during  or  within  6  weeks  before  the  study.  Before 
the  study  began,  subjects  had  abstained  from  short-acting  β
-adrenergic  bronchodilators  for  at  least  6  hours,  long-acting  β
-adrenergic  bronchodilators  for  a  minimum  of  48  hours, 
short-acting  antihistamines  for  4  days,  and  leukotriene  modifiers 
for  48  hours.  The  control  group  consisted  of  10  adult  subjects 
with  normal  spirometry  and  negative  MBPT. 
This  study  was  approved  by  the  Institutional  Review  Board  of 
Eulji  Hospital. 
Study  design
Before  the  provocation  study,  spirometry  was  performed  to 
ensure  that  FEV1  was  65%  or  greater  of  the  predicted  value 
and  within  ±10%  of  the  value  measured  in  the  previous  study. 
The  bronchial  provocation  test  was  performed  with  BAC 
following  a  method  modified  from  that  used  by  Asmus  and 
colleagues
4).  The  subject  inhaled  3  mL  of  0.9%  NaCl  solution 
and  then  3  mL  of  0.9%  NaCl  solution  containing  600  μg  of 
BAC  (Sigma,  St.  Louis,  MO,  U.S.A.).  The  solutions  were 
prepared  using  aseptic  techniques  and  stored  at  2  C  in  an 
Eppendorf  tube.  They  were  allowed  to  warm  to  room 
temperature  immediately  prior  to  use.  Each  3  mL  dose  was 
inhaled  using  normal  tidal  breathing  through  a  DeVilbiss  646 
nebulizer  (DeVilbiss  Co.,  Somerset,  PA,  U.S.A.).  Vmax22
Ⓡ 
spirometry  (SensorMedics,  Yorba  Linda,  CA,  U.S.A.)  was 
performed  15  minutes  after  the  inhalation  of  each  dose  began. 
The  provocation  was  repeated  every  20  minutes  until  FEV1 
decreased  by  at  least  15%  or  until  a  maximum  of  three  doses 
had  been  administered.  BAC-induced  bronchoconstriction  was 
defined  as  a  decrease  of  15%  or  more  in  FEV1  after  each  BAC 
inhalation.  To  compare  differences  in  BAC-induced  bronchoco-
nstriction  according  to  airway  responsiveness,  asthmatics  with 
PC20  less  than  4.0  mg/mL  were  also  analyzed  as  a  separate 
subgroup.
The  subjects  were  given  100  μg  of  albuterol  (Ventolin
Ⓡ 
evohaler,  GlaxoSmithKlein,  Middlesex,  U.K.)  with  a  metered- 
dose  inhaler  to  reverse  bronchoconstriction  if  it  occurred  or  on 
request.  The  albuterol  dose  was  repeated,  if  necessary,  20 
minutes  later. 
Statistics
Basal  characteristics  between  the  asthmatic  and  control 
groups  were  compared  by  a  Student's  t-test  for  continuous 
variables  and  a  chi-square  test  for  categorical  variables.  BAC- 
induced  decreases  in  FEV1  and  differences  in  broncho-
constriction  between  groups  were  divided  by  means  of  airway 
sensitivity  and  compared  using  a  paired  t-test  and  a  Mann- 
Whitney  test,  respectively.  We  used  the  SPSS  software  package 
(SPSS  11.0.0,  SPSS  Inc.,  Chicago,  IL,  U.S.A.)  and  a  p  value  of 
<0.05  was  considered  statistically  significant.
RESULTS
There  were  no  significant  differences  in  age,  sex,  FEV1  % 
predicted  value,  or  smoking  status  between  asthmatic  patients 
and  control  subjects  (Table  1).  A  total  of  three  BAC  inhalations, 
for  a  cumulative  dose  of  1,800  g,  was  given  to  30  patients  and 
10  normal  control  participants;  among  the  30  patients,  two  did 
not  inhale  the  3
rd  BAC  solution  because  their  decreased  FEV1 
exceeded  15%  of  the  baseline  value. 
The  mean  FEV1  values  at  baseline,  1
st,  2
nd  and  3
rd  inhalation 
were  2.36  L±0.74  L,  2.26  L±0.64  L,  2.18  L±0.63  L  and  2.17 
L±0.65  L  in  asthmatics,  and  3.32  L±0.91  L,  3.33  L±0.82  L, 
3.33  L±0.90  L  and  3.34  L±0.85  L  in  the  control  group,  respec-
tively.  In  asthmatics,  the  mean  percent  fall  in  FEV1  after  each 
inhalation  was  2.69%,  5.36%,  and  5.30%,  respectively.  FEV1 
after  the  1
st  and  the  2
nd  inhalations  decreased  significantly  from 
the  previous  value  (p=0.001,  p=0.001),  but  there  was  no 
difference  between  FEV1  after  the  2
nd  and  3
rd  inhalation 
(p=0.973)  (Figure  1).  There  were  no  significant  changes  in  FEV1 
in  the  control  group.
BAC-induced  bronchoconstriction  (a  decrease  of  FEV1  by 
15%  or  more)  was  found  in  6  patients  (6/30,  20%),  with  2 
responders  after  the  2
nd  inhalation  and  4  after  the  3
rd  inhalation. 
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Asthmatics  (n=30) Normal  controls  (n=10)
Age  (yr)
Male,  n  (%)
Never  smoker,  n  (%)
FVC  (L)
FVC  (%  of  predicted)
FEV1  (L)
FEV1  (%  of  predicted)
Methacholine  PC20,  (n=10,  mg/mL)
%  change  of  post  bronchodilator  FEV1  (n=20,  %)
45.9±15.7
20  (67)
14  (46)
3.6±0.9
94±16
2.4±0.7
74±19
5.95  (0.77-20.0)*
16.5  (12-26)*
42.0±21.4
7  (70)
4  (40)
4.1±1.1
103±8
3.3±0.9
87±11
Not  done
Not  done
Data  are  expressed  as  means±SD  unless  otherwise  noted.  There  were  no  significant  differences  between  the  two  groups.
*  :  median  (range).
Table  1.  Subject  characteristics
Figure 1. Course of mean % change in FEV1 after inhaling BAC in 
asthmatics  and  controls.  Changes  of  FEV1  after  BAC  inhalation 
were cumulative up to 1200 μg and reached a plateau. There was 
no  significant  bronchoconstriction  in  the  control  group. 
* :  p<0.01,  compared  with  baseline  value.
† :  p<0.01,  compared  with  600  μg  BAC
Figure  2.  %  change  of  FEV1  after  inhaling  BAC  according  to  the 
sensitivity of airway responsiveness (PC20 less than 4.0 mg/mL or 
not).  A  significant  change  in  FEV1  between  the  two  groups  was 
observed  only  after  the  1st  inhalation.
*:  p<0.05. 
coughing,  chest  discomfort,  or  dyspnea  shortly  after  BAC 
inhalation,  and  these  symptoms  were  relieved  effectively  by 
short-acting  β2-agonist  inhalation.
BAC-induced  FEV1  changes  in  the  subgroup  with  high 
airway  sensitivity  (PC20  less  than  4.0  mg/mL)  were  only 
significantly  different  from  other  asthmatics  after  the  1
st  BAC 
inhalation  (p=0.038)  (Figure  2).
DISCUSSION
BAC-induced  decreases  in  FEV1  were  cumulative  up  to 
1,200  μg  and  the  reached  a  plateau,  with  significant  broncho-
constriction  (decrease  of  FEV1  ≥15%)  occuring  in  6  of  the  30 
patients  with  stable  bronchial  asthma  (6/30,  20%).  BAC-induced 
bronchoconstriction  was  initially  more  severe  in  patients  with 
more  sensitive  airway  responsiveness,  but  this  trend  disappeared 
with  additional  BAC  doses.  BAC-induced  bronchoconstriction 
was  easily  reversed  with  a  short-acting  β2-agonist.
BAC-induced  bronchoconstriction  is  cumulative,  prolonged, 
and  determined  by  basal  airway  responsiveness
5, 6).  Zhang  and 
colleagues  reported  that  the  range  of  BAC  PC20  FEV1  was  0.03 
to  5.5  μmol  (1  μmol  is  equivalent  to  354  μg  of  BAC).  When 
they  repeatedly  doubled  the  BAC  concentration  from  0.044  to 
5.64  μmol,  bronchoconstrictions  (≥10%  fall  in  FEV1)  developed 
in  25  of  28  subjects  during  a  BAC  inhalation  challenge,  and  17 
of  28  subjects  showed  at  least  a  20%  decrease  of  FEV1.  The 
dose-response  to  BAC  was  steep  and  did  not  appear  to 
plateau.  There  was  also  a  significant  correlation  between 
histamine  PC20  FEV1  and  BAC  PC20  FEV1
6). 
The  results  of  Asmus  and  colleagues  confirmed  the 
observations  of  previous  investigators;  10  (55%)  of  18  subjects 
showed  at  least  a  20%  decrease  in  FEV1
4).  They  increased  the 
inhaled  dose  of  BAC  from  600  to  2,400  μg  with  respective 
inhalations  of  600  μg  of  BAC  at  20-minute  intervals.  This 
cumulative  manner  of  BAC  inhalation  more  closely  approxi-
mates  the  clinical  situation  than  the  method  employed  in  the 
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study  of  Zhang  and  colleagues.  In  the  latter  study,  the  authors 
intended  to  calculate  BAC  PC20  FEV1,  and  the  dose  of  BAC 
was  doubled  as  in  the  dosing  method  of  the  methacholine 
provocation  test.
There  are  some  notable  differences  between  the  results  of 
our  study  and  previous  results.  First,  we  found  that  broncho-
constriction  due  to  BAC  inhalation  reached  a  plateau  after  a 
cumulative  BAC  dose  of  1,200  μg.  Whereas  asthmatics  with 
moderate  to  severe  bronchial  hyperresponsiveness  were 
selected
6),  our  study  included  patients  with  mild  bronchial 
hyperresponsiveness,  who  may  be  less  sensitive  to  BAC 
inhalation,  allowing  dosing  to  reach  a  plateau.  Second,  the 
difference  in  BAC-induced  bronchoconstriction  was  not 
maintained  with  additional  doses  in  patients  more  severe  airway 
responsiveness  (PC20  less  than  4.0  mg/mL).  A  significant 
difference  was  observed  only  at  the  1
st  inhalation  of  BAC  600  μ
g,  with  bronchoconstriction  reaching  a  plateau  earlier  in  these 
patients  (Figure  2).  Further  studies  are  needed  to  clarify  this 
difference. 
The  mechanism  of  BAC-induced  bronchoconstriction  is  not 
clear
1).  The  main  controversy  is  whether  the  dominant  mode  of 
action  is  IgE-dependent  or  non-IgE-dependent  mediator 
release.  A  positive  intradermal  test  result  with  BAC  implies  an 
IgE-mediated  response
9, 10),  but  BAC  can  elicit  non-IgE 
mediated  histamine  release  from  rat  mast  cells  and  its 
bronchoconstriction  can  be  blocked  by  antihistamines
9, 11). 
The  bronchoconstrictive  effects  of  BAC  were  originally 
described  after  inhalation  of  an  ipratropium  bromide  nebulizer 
solution  that  contained  250  μg/mL  BAC
3).  Ipratropium  is  now 
only  available  as  a  preservative-free  solution.  Previously,  a 
non-sterile,  screwcap  unit-dose  albuterol  nebulizer  solution  that 
contained  300  μg  of  BAC  per  2.5  mg  dose  of  albuterol  was  on 
the  market,  but  it  is  no  longer  available. 
Metered  dose  inhalers  now  contain  no  preservatives.  A 
recently  introduced  propellant-free  and  multi-dose  inhalation 
device,  the  Respimat
Ⓡ  Soft  Mist  Inhaler
TM  (SMI),  uses  BAC  and 
EDTA  as  preservatives.  The  amount  of  BAC  delivered  to  the 
lungs  in  a  single  actuation  is  0.44  μg,  which  is  approximately 
200  times  lower  than  that  delivered  by  wet  nebulizer  solutions. 
Patel  et  al
12)  reported  that  the  decreases  of  FEV1  in  asthmatics 
with  airway  hyper-reactivity  by  four  actuations  of  an  aqueous 
placebo  that  contained  no  bronchodilator  (12  μL  water  +  5.5  μ
g  EDTA  +  1.1  μg  BAC/actuation)  via  Respimat
Ⓡ SMI  were  not 
different  from  decreases  of  FEV1  by  normal  saline  (-0.121  L  vs. 
-0.094  L;  90%  CI  -0.107～0.052  L,  within  a  pre-determined 
equivalence  region  of  ±0.15  L).
In  clinical  practice  in  Korea,  rapid-acting  β2-agonists  for 
nebulization  are  available  in  sterile  unit-dose  screwcap  vials  and 
a  nonsterile  multidose  dropper  bottle  (Ventolin
Ⓡ  respiratory 
solution,  GlaxoSmithKline,  U.K.).  The  latter  contains  50  μg  BAC 
in  each  2.5  mg  dose  of  albuterol,  and  its  manufacturer 
recommends  using  2.5-5  mg  of  albuterol  by  nebulization  in  a 
proper  clinical  setting.  According  to  GINA  (Global  INitiative  for 
Asthma  management  and  prevention)  guidelines  for 
hospital-based  management  of  asthma  exacerbation,  rapid 
acting  β2-agonist,  generally  administered  by  nebulization,  can 
be  given  at  one  dose  every  20  minutes  for  1  hour
13).  Therefore, 
if  a  nonsterile  multidose  dropper  bottle  is  used,  inhalation  of 
BAC  150-300  μg  is  possible  over  1  hour. 
In  the  present  study,  the  median  value  of  the  %  decrease  of 
FEV1  after  inhalation  of  600  μg  BAC  was  2.86%  (range:  -5.0～
11.9).  Thus,  the  currently  available  multi-dose  dropper  bottled 
albuterol  is  generally  safe  if  used  according  to  the  recom-
mended  directions.  However,  for  asthmatics  with  severe  airway 
responsiveness,  a  paradoxical  bronchoconstriction  can  occur  at 
a  relatively  low  BAC  dose.  In  a  clinical  situation,  if  there  is  no 
response  to  a  sufficient  dose  of  BAC-containing  bronchodilator 
solution  or  if  dyspnea  is  paradoxically  aggravated,  BAC-induced 
bronchoconstriction  should  be  considered.  A  bronchial 
provocation  test  with  the  actual  dose  of  BAC  included  in 
currently-used  nebulizer  solutions  to  patients  with  more  severe 
bronchial  hyperresponsiveness  will  show  more  clinically 
meaningful  results.
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